NeuroVoices

The duo from Vanderbilt University shared background on their recently published study that found novel associations between functional seizures, cerebrovascular disease, and other psychiatric disorders.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine detailed his study on the correlations between sleep and cognitive decline in middle-aged Hispanics.

The clinical fellow at Massachusetts General Hospital detailed his research on neurology resident EEG education, and the increased need for more consistency throughout programs.

Raymond Sanchez, MD, chief medical officer of Cerevel Therapeutics, discussed tavapadon, a drug intended to treat Parkinson disease that is currently being tested in a slew of clinical trials.

Jennifer Robblee, MD, neurologist, Barrow Neurological Institute, shares her takeaways about how migraine care shifted this year and how it may continue to shift going forward.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the findings of a phase 2 trial using ezogabine, a drug once FDA-approved to treat epilepsy, in patients with ALS.

Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.

Christian Meisel, MD, PhD, department of neurology, Universitätsmedizin Berlin, and Berlin Institute of Health, discussed the landscape for devices that forecast seizures, including the use of multi-modal wristband sensors.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center sat down to discuss a multitude of topics surrounding Infantile Spasms Awareness Week.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

The vice president of Clinical Research at Eisai provides updates on the MOMENTUM trials which will examine lorcaserin as a potential treatment for patients with Dravet syndrome.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD GENEration initiative tackles 1 of the greatest unmet needs for patients with Parkinson disease.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

The professor of neurology at the NYU Langone Grossman School of Medicine discussed a recent study she and colleagues conducted on new neurological disorders in patients with COVID-19.